NASDAQ
0.28USD
+0.04 (+14.37%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
11.5M
P/E
—
EPS
—
Beta
0.40
52W range
0.2-5.14
Day range
0.26–0.32
Open
0.27
Prev close
0.24
Volume
111.1M
Avg volume
2M
Dividend
0.00
IPO
2011-06-21
https://www.globenewswire.com/news-release/2026/08/04/3338076/0/en/SRX-Global-Acquires-Stake-in-Vistagen-Therapeutics-NASDAQ-VTGN.html · 8/4/2026+0.60
https://www.prnewswire.com/news-releases/kuehn-law-encourages-investors-of-vistagen-therapeutics-inc-to-contact-law-firm-302787406.html · 6/1/2026-1.00
https://www.businesswire.com/news/home/20260316295010/en/CLASS-ACTION-DEADLINE-TONIGHT-MONDAY-MARCH-16-Faruqi-Faruqi-LLP-Reminds-Vistagen-Therapeutics-Investors-of-the-Securities-Class-Action-Lawsuit-Deadline-Tonight/ · 3/16/2026-0.80
https://www.newsfilecorp.com/release/288622/VTGN-DEADLINE-ROSEN-NATIONAL-INVESTOR-COUNSEL-Encourages-Vistagen-Therapeutics-Inc.-Investors-to-Secure-Counsel-Before-Important-March-16-Deadline-in-Securities-Class-Action-VTGN · 3/16/2026-1.00
https://www.globenewswire.com/news-release/2026/03/12/3254931/9788/en/Bronstein-Gewirtz-Grossman-LLC-Urges-Vistagen-Therapeutics-Inc-Investors-to-Act-Class-Action-Filed-Alleging-Investor-Harm.html · 3/12/2026-1.00
https://www.prnewswire.com/news-releases/vtgn-shareholder-reminder-faruqi--faruqi-llp-reminds-vistagen-therapeutics-vtgn-investors-of-securities-class-action-deadline-on-march-16-2026-302710131.html · 3/11/2026-1.00
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-vistagen-therapeutics-inc-of-class-action-lawsuit-and-upcoming-deadlines--vtgn-302705891.html · 3/5/2026-1.00
https://www.prnewswire.com/news-releases/the-gross-law-firm-notifies-vistagen-therapeutics-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline--vtgn-302701611.html · 3/3/2026-1.00
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-vistagen-therapeutics-inc-of-class-action-lawsuit-and-upcoming-deadlines--vtgn-302698899.html · 2/26/2026-1.00
https://www.newsfilecorp.com/release/284849/ROSEN-RECOGNIZED-INVESTOR-COUNSEL-Encourages-Vistagen-Therapeutics-Inc.-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-VTGN · 2/23/2026-1.00
https://www.prnewswire.com/news-releases/vtgn-deadline-alert-faruqi--faruqi-llp-reminds-vistagen-therapeutics-vtgn-investors-of-securities-class-action-deadline-on-march-16-2026-302693878.html · 2/21/2026-1.00
https://www.globenewswire.com/news-release/2026/02/19/3241267/683/en/VTGN-INVESTOR-ALERT-Faruqi-Faruqi-LLP-Reminds-Vistagen-Therapeutics-Investors-of-the-Securities-Class-Action-Lawsuit-Deadline-on-March-16-2026.html · 2/19/2026-1.00
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
